XML 10 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
CURRENT ASSETS    
Cash and cash equivalents $ 702 $ 584
Accounts and grants receivable, net 12 25
Prepaid expenses and other current assets 1,011 1,625
Total current assets 1,725 2,234
Deposits 50 50
Intangible assets, net 804 870
TOTAL ASSETS 2,579 3,154
CURRENT LIABILITIES    
Accounts payable and accrued liabilities 682 771
Loan due to Juvenescence, net of debt issuance costs, current portion 6,968 7,140
Related party payables, net 69 70
Warrant liability 1,033
Insurance premium liability and other current liabilities 333 986
Total current liabilities 9,085 8,967
Loan due to Juvenescence, net of debt issuance costs, net of current portion 6,756 6,062
TOTAL LIABILITIES 15,841 15,029
Commitments and contingencies (Note 11)
STOCKHOLDERS’ DEFICIT    
Preferred stock, $0.0001 par value, authorized 5,000 shares; none issued and outstanding as of June 30, 2022 and December 31, 2021
Common stock, $0.0001 par value, 100,000 shares authorized; and 37,945 and 37,941 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively 4 4
Additional paid-in capital 97,850 93,912
Accumulated deficit (111,072) (105,748)
AgeX Therapeutics, Inc. stockholders’ deficit (13,218) (11,832)
Noncontrolling interest (44) (43)
Total stockholders’ deficit (13,262) (11,875)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 2,579 $ 3,154